Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
about
Cooperative epigenetic modulation by cancer amplicon genesThe role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignanciesLestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosisSB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaTargeting histone deacetyalses in the treatment of B- and T-cell malignancies.PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genesPrognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.Targetable molecular pathways in classical Hodgkin's lymphoma.Nuclear JAK2: form and function in cancer.JAK2 inhibition for the treatment of hematologic and solid malignancies.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.JAK-STAT in lipid metabolism of adipocytes.Structural genomic alterations in primary mediastinal large B-cell lymphoma.STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.HiJAKing the epigenome in leukemia and lymphoma.A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.Activation of Stat3 in renal tumors.Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays.Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.
P2860
Q24608701-0FC979D6-D94B-4F82-BD3C-AD55103853C8Q27008221-1147F8A8-CB01-467A-9183-7EEEDD9B656DQ33886243-96168A0E-00BF-482C-8026-E3C763315492Q34194226-5453FC98-6E6F-40A3-A527-0F8B7869CBE4Q34287747-06CDDDCB-710E-4C13-8DF3-83A080380EDAQ34414452-FA097C50-77C5-45F2-AD3A-FF7936055F04Q36117194-4A8A37A0-D8FB-4ADE-8989-0C02DF2A1302Q37505538-05B6CB75-8C9A-471A-B6B5-121AD23A9C2CQ37635115-2DF16D37-781E-45AD-A59D-C6F916E4DFFFQ37716643-2177FA87-3EB3-4F79-BE7E-456B59308FA6Q37810947-981ACE54-B2A5-40A1-9197-9C95CD3E84C3Q37825891-DDD8B5E6-0C6C-4542-8D76-267DABB594DDQ37910092-1DD4EEEB-4980-48F3-BAFF-EE60A7D51BE2Q38001733-3F5564E4-3B3A-41C8-86D0-9283CE004764Q38164139-42C80BEF-80C1-4679-B400-EF4E778712A1Q38185398-A5668601-3408-4964-9D37-71C28904F8EBQ38267888-40DAEE70-819D-46E6-86D2-8694C93CC081Q38317603-F696DAC8-17A9-4456-9E0E-109DAFE48B0FQ38771110-7E80493D-9FC2-408D-8303-C7E88E45E11DQ39017147-D31A35AB-1A90-4BA1-8C0B-2DB996D38271Q39170500-87672F07-9CB7-48E5-A8A7-F0DD4A79C7ACQ39237403-68D1D3BE-9714-4D79-9C3E-45A871986644Q41600132-8706A4C0-3842-4D29-9DA2-1D4B3C0AEE35Q41865091-CBB488D6-9B7E-4198-B0A9-897A35C5E017Q42013920-FE4C6579-3677-447E-84E7-1E1880C69F5AQ49912597-03929A77-5C5B-4314-B66B-2A5A60C94746Q50790201-FDD15A3F-5CC4-4E31-B64A-623819ABD5B3Q51511968-C9E476F3-974B-4759-8049-B341E08313D4Q52885667-8DA497DA-4453-4744-96A4-B043D331504CQ54216481-7DE2A199-F9CA-462F-8F8D-505D5EE369E3Q54724626-EF51A0B7-7244-45C2-A9AE-5D4F530157EAQ54977480-F6CAD560-55C6-4538-83DB-C00B196B36BD
P2860
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@en
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@nl
type
label
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@en
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@nl
prefLabel
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@en
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@nl
P2093
P2860
P1433
P1476
Recurrent numerical aberration ...... AK2-STAT cascade in lymphomas.
@en
P2093
Andreas Reiter
Caroline Bourgau
Cecile Meier
Juerg Schwaller
Petra Hirschmann
Philip Went
Stefano A Pileri
Stephan Dirnhofer
Sylvia Hoeller
P2860
P2888
P304
P356
10.1038/MODPATHOL.2008.207
P577
2009-01-09T00:00:00Z